National Institutes of Health: Sclerosis trials

The registry lists 65 Sclerosis studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 1 14Phase 2 29Phase 3 7No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PET Imaging of Cyclooxygenase in Multiple SclerosisTerminatedNCT05062083Phase 2Results posted
• Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple SclerosisActive, not recruitingNCT04742400Phase 2Results posted
• Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple SclerosisCompletedNCT04025554Phase 1/2Results posted
• HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02437110Phase 1Results posted
• Idebenone for Primary Progressive Multiple SclerosisCompletedNCT01854359Phase 1/2Results posted
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
• A Cooperative Clinical Study of Abatacept in Multiple SclerosisCompletedNCT01116427Phase 2Results posted
• Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)CompletedNCT01086540Phase 2Results posted
• Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)CompletedNCT00950248Phase 1/2Results posted
• Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT00702689Phase 2Results posted
• Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous TherapyCompletedNCT00381940Phase 2Results posted
• High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) StudyCompletedNCT00288626Phase 2Results posted
• Scleroderma: Cyclophosphamide or TransplantationCompletedNCT00114530Phase 2/3Results posted
• Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple SclerosisCompletedNCT00094172Phase 2Results posted
• Natural History of Multiple Sclerosis and Its MimickersCompletedNCT02504840
• Oral Guanabenz for Multiple SclerosisTerminatedNCT02423083Phase 1
• Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple SclerosisCompletedNCT02330965
• Natural History of Optic NeuritisTerminatedNCT01851434
• Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisCompletedNCT01326715Phase 1
• Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)CompletedNCT01143441Phase 1
• Studies of Autistic Patients: Gene Networks and Clinical SubtypesTerminatedNCT01092208
• Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate MofetilCompletedNCT00853788
• Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
• Brain Peripheral Benzodiazepine Receptors in Patients With Multiple SclerosisCompletedNCT00432900Phase 1
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00393588
• Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple SclerosisCompletedNCT00342134Phase 2
• Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral SclerosisCompletedNCT00339976
• Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral SclerosisCompletedNCT00334516
• Biomarkers in Multiple SclerosisCompletedNCT00325988
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00321568
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00099307
• Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorTerminatedNCT00095329Phase 1/2
• The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis PatientsCompletedNCT00094068
• Safety of RG2077 in Patients With Multiple SclerosisCompletedNCT00076934Phase 1
• Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT00071838Phase 2
• Brain Function in Primary Lateral SclerosisCompletedNCT00071435
• Creatine for the Treatment of Amyotrophic Lateral SclerosisCompletedNCT00070993Phase 2
• Treatment of Multiple Sclerosis Using Over the Counter InosineCompletedNCT00067327Phase 2
• MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple SclerosisCompletedNCT00064909
• Improving Memory in Patients With Multiple SclerosisWithdrawnNCT00062972Phase 3
• Minocycline to Treat Amyotrophic Lateral SclerosisCompletedNCT00047723Phase 3
• Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple SclerosisCompletedNCT00043264Phase 2
• Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma PatientsTerminatedNCT00040651Phase 1
• Treatment of Multiple Sclerosis With Copaxone and AlbuterolCompletedNCT00039988Not applicable
• Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral SclerosisCompletedNCT00023075
• Screening and Natural History: Primary Lateral Sclerosis and Related DisordersCompletedNCT00015444
• Rolipram to Treat Multiple SclerosisCompletedNCT00011375Phase 2
• Yoga: Effect on Attention in Aging & Multiple SclerosisCompletedNCT00010998Phase 2
• Natural Antioxidants in the Treatment of Multiple SclerosisCompletedNCT00010842Phase 1/2
• Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic SclerosisStatus unknownNCT00006393
• Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple SclerosisStatus unknownNCT00006060
• Clinical Trial of Creatine in Amyotrophic Lateral SclerosisCompletedNCT00005766Phase 2
• Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]CompletedNCT00005674Phase 2
• A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple SclerosisCompletedNCT00004816Phase 1
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple SclerosisCompletedNCT00004814Phase 3
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT00004786Phase 3
• Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron DiseaseCompletedNCT00004771Phase 2
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple SclerosisCompletedNCT00004744Phase 3
• Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneStatus unknownNCT00004645Phase 3
• Determinants of Disease Severity in Amyotrophic Lateral SclerosisStatus unknownNCT00004457
• Phase II Study of Recombinant Relaxin for Progressive Systemic SclerosisCompletedNCT00004380Phase 2
• Zenapax to Treat Multiple SclerosisCompletedNCT00001934Phase 2
• Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)CompletedNCT00001781Phase 2
• A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) PatientsCompletedNCT00001669Phase 2
• Assessment of Patients With Multiple Sclerosis (MS)CompletedNCT00001156